UNIPRINT.NET
12.4.2016 15:49:48 CEST | Business Wire | Press release
UniPrint.net Corp , industry leader in printing virtualization technology, today announces the release of 3 print appliances – UniPrint Infinity™ vPad Pro, vPad Touch, and vPad CE . The multi-purpose, printer-vendor independent appliances are designed to enable on demand printing with security, and low maintenance and high speed remote printing across offices and geo locations, while the UniPrint Infinity printing software is in use. UniPrint Infinity vPads can also replace remote site or branch Windows print servers, making the process of consolidation into the data center much simpler, and ongoing IT support costs of remote print servers a thing of the past.
With the advent of cloud technology, an increasing number of organizations are moving to consolidate their data centers, be it on-premises or off-premises, in an effort to reduce IT support costs, provide centralized administration, and secure data and printer access. Yet remote print servers have remained a burden to manage and a challenge to support, especially when combined with frequent changes and updates, causing remote print speed issues and security implications for businesses with dispersed locations.
These industry-first vPads feature dual security via 256 bit encryption, user-authenticated print release, and print stream compression which reduces print data sizes by up to 95%, promoting fast data transmission and printing at remote sites . They can also act as remote print server gateway devices, eliminating the need to procure and support Windows hardware and software in remote locations.
“These simple, plug and play devices are game changers. They help to unleash the true power of the UniPrint Infinity software, allowing enterprise users to print in an unprecedentedly secure and speedy way. The 3 models allow the customers to have the best choice and within budget,” noted UniPrint.net Chief Technical Officer Arron Fu.
The vPads can provide support to multiple printers and are compatible with any computing environment. Installation is a straightforward plug and play, and no configuration is required by any personnel in the remote site.
For further information on UniPrint Infinity and vPads, or to download a free product trial, please visit www.uniprint.net or email sales@uniprint.net . Alternatively, sign up for our free 30-minute webinar “Do you Really Need Remote Print Servers?” April 21, 2016 at 1:00 PM U.S. Eastern Standard Time.
About UniPrint.net
UniPrint.net is the recognized leader in printing virtualization. The newest solution in UniPrint’s patented, award-winning product line, UniPrint Infinity v9 is the industry’s first truly secure enterprise-wide solution for any computing environment. Enabling anywhere, anytime, any device secure pull printing, UniPrint Infinity comes with proven ROI through its statistics module, print document archiving functionality and secure mobile printing modules, and high availability with load balancing. UniPrint Infinity replaces all manufacturer printer drivers with a single PDF generator to promote faster, more efficient printing, helping organizations to improve both productivity and return on investments.
UniPrint and UniPrint Infinity are the trademarks of UniPrint.net. All other trademarks and registered trademarks are properties of their respective owners.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160412006028/en/
Contact:
UniPrint.net
Katherine Cheung, Marketing Manager, +1 416-503-9800
ext. 8566
katherine.cheung@uniprint.net
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom